Dr. Richard Isaacson was featured by CNN discussing new research that helps translate the benefits of recently approved Alzheimer’s medications into outcomes that matter most to patients and families: maintaining independence. The article examines how treatments such as lecanemab and donanemab may extend the amount of time people with early Alzheimer’s disease can continue managing everyday activities, including driving, handling finances, preparing meals, and living independently.

Dr. Isaacson emphasized that these therapies represent meaningful progress, while also setting realistic expectations for patients considering treatment. As he noted, “These are not miracle drugs… All that happens is that people get less worse over time.” He also highlighted the importance of using understandable, patient-centered measures to help individuals and families make informed decisions about Alzheimer’s treatment.

Read the full CNN article to learn how new Alzheimer’s therapies may help people preserve their independence for longer while researchers continue advancing the field.